Ovarian Cancer
Oncology 5 original drugsPhase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q4 2026
Plasmodium immunotherapy
CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.
Estimated · stale NCT05924776
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 12 mechanisms across 45 industry trials with a known mechanism of action.
Poly(ADP-Ribose) Polymerase Inhibitor
11 trials 4 active 2 sponsors
Microtubule Inhibitor
8 trials 1 active 6 sponsors
Programmed Death Receptor-1 Blocking Antibody
7 trials 1 active 4 sponsors
Platinum-based Drug
5 trials 1 active 4 sponsors
Vascular Endothelial Growth Factor Inhibitor
4 trials 1 active 3 sponsors
Programmed Death Ligand-1 Blocker
3 trials 1 active 2 sponsors
DNA
2 trials 1 active 2 sponsors
ALK/ROS1/NTRK1/TRKB/TRKC
1 trials 1 active 1 sponsor
AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3
1 trials 1 active 1 sponsor
PIK3CA
1 trials 1 sponsor
Alkylating Drug
1 trials 1 sponsor
Nuclear Export Inhibitor
1 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
636 industry-sponsored trials across 318 sponsors
Showing 3 of 3 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| On Target Laboratories, LLC | CYTALUX (pafolacianine) injection | — | NOT YET RECRUITING | 2026-11-30 | NCT07469202 |
| AstraZeneca | Olaparib | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | COMPLETED | 2022-09-30 | NCT04330040 |
| AstraZeneca | Olaparib | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | COMPLETED | 2020-04-17 | NCT02476968 |
Showing 87 of 87 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | SHR-A1921 | — | RECRUITING | 2026-05-31 | NCT06394492 |
| Genelux Corporation | olvimulogene nanivacirepvec | — | RECRUITING | 2026-06 | NCT05281471 |
| NX Development Corp | Gleolan | — | RECRUITING | 2027-01 | NCT05804370 |
| Hansoh BioMedical R&D Company | HS-20089 | — | RECRUITING | 2027-03-07 | NCT06855069 |
| AbbVie | Mirvetuximab soravtansine plus Bevacizumab | — | RECRUITING | 2027-04 | NCT05445778 |
| Jiangsu HengRui Medicine Co., Ltd. | SHR-A1811 | — | RECRUITING | 2027-05 | NCT06828354 |
| Sichuan Baili Pharmaceutical Co., Ltd. | BL-B01D1 | — | RECRUITING | 2027-06 | NCT06994195 |
| K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Investigator's choice of Chemotherapy | — | RECRUITING | 2028-05-31 | NCT07546500 |
| Genmab | Rina-S | — | RECRUITING | 2028-10 | NCT07225270 |
| Verastem, Inc. | avutometinib | — | RECRUITING | 2028-10-15 | NCT06072781 |
| Daiichi Sankyo | Trastuzumab Deruxtecan | — | RECRUITING | 2028-11-01 | NCT06819007 |
| Incyte Corporation | INCB123667 | — | RECRUITING | 2028-11-15 | NCT07214779 |
| AstraZeneca | AZD5335 | — | RECRUITING | 2028-11-17 | NCT07218809 |
| Merck | Sacituzumab tirumotecan | — | RECRUITING | 2029-04-27 | NCT06824467 |
| GE Healthcare | GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | — | RECRUITING | 2029-06 | NCT07219238 |
| Imunon | IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) | — | RECRUITING | 2032-10-31 | NCT06915025 |
| Merck | Sacituzumab tirumotecan | — | RECRUITING | 2033-02-25 | NCT07318558 |
| Chipscreen Biosciences, Ltd. | chiauranib | — | RECRUITING | 2024-12-31 | NCT04921527 |
| AstraZeneca | Olaparib | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2026-07-27 | NCT04884360 |
| Pfizer | Avelumab | Programmed Death Ligand-1 Blocker [EPC] | ACTIVE NOT RECRUITING | 2026-09-30 | NCT05059522 |
| CanariaBio Inc. | Oregovomab | — | ACTIVE NOT RECRUITING | 2026-12-26 | NCT04498117 |
| Genmab | Rina-S | — | ACTIVE NOT RECRUITING | 2027-02 | NCT06619236 |
| AstraZeneca | Olaparib | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2027-04-06 | NCT04421963 |
| Novita Pharmaceuticals, Inc. | NP-G2-044 | — | ACTIVE NOT RECRUITING | 2028-10-25 | NCT07109414 |
| BeiGene | Pamiparib capsule | — | ACTIVE NOT RECRUITING | 2025-12-01 | NCT03519230 |
| AstraZeneca | Bevacizumab | Vascular Endothelial Growth Factor Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2025-03-28 | NCT03737643 |
| Merck | Pembrolizumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | ACTIVE NOT RECRUITING | 2025-03-05 | NCT05116189 |
| Cordgenics, LLC | Standard Chemotherapy | — | ACTIVE NOT RECRUITING | 2024-06-30 | NCT03949283 |
| pharmaand GmbH | Rucaparib | — | ACTIVE NOT RECRUITING | 2024-05-20 | NCT03522246 |
| Impact Therapeutics, Inc. | IMP4927 | — | ACTIVE NOT RECRUITING | 2023-03-16 | NCT04169997 |
| AstraZeneca | Olaparib 300mg tablets | — | ACTIVE NOT RECRUITING | 2018-05-17 | NCT01844986 |
| AstraZeneca | Olaparib 300mg tablets | — | ACTIVE NOT RECRUITING | 2016-09-19 | NCT01874353 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | SHR-1921 | — | NOT YET RECRUITING | 2026-06-15 | NCT06211023 |
| CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. | Plasmodium immunotherapy | — | NOT YET RECRUITING | 2026-11-30 | NCT05924776 |
| Jiangsu Alphamab Biopharmaceuticals Co., Ltd | JSKN003 | — | NOT YET RECRUITING | 2026-12-30 | NCT06751485 |
| Sichuan Baili Pharmaceutical Co., Ltd. | BL-M07D1 | — | NOT YET RECRUITING | 2028-12 | NCT07545460 |
| Genmab | Rina-S | — | NOT YET RECRUITING | 2029-12 | NCT07564141 |
| Jina Pharmaceuticals Inc. | Paclitaxel Lipid Suspension | — | NOT YET RECRUITING | 2025-12 | NCT06867562 |
| AGO Research GmbH | Bevacizumab | Vascular Endothelial Growth Factor Inhibitor [EPC] | COMPLETED | 2025-03-11 | NCT03353831 |
| AstraZeneca | Olaparib 300mg tablets | — | COMPLETED | 2025-01-27 | NCT03534453 |
| Merck | Pembrolizumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | COMPLETED | 2024-08-26 | NCT03740165 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | BD0801 | — | COMPLETED | 2023-12-08 | NCT04908787 |
| NovoCure Ltd. | Paclitaxel | Microtubule Inhibitor [EPC] | COMPLETED | 2023-05-18 | NCT03940196 |
| pharmaand GmbH | Rucaparib | — | COMPLETED | 2023-03-08 | NCT04676334 |
| AbbVie | Mirvetuximab Soravtansine | — | COMPLETED | 2023-03-06 | NCT04209855 |
| Vascular Biogenics Ltd. operating as VBL Therapeutics | VB-111 + Paclitaxel | — | COMPLETED | 2022-07-19 | NCT03398655 |
| Roche | Paclitaxel | Microtubule Inhibitor [EPC] | COMPLETED | 2022-02-08 | NCT03038100 |
| Jiangsu HengRui Medicine Co., Ltd. | Fluzoparib capsules | — | COMPLETED | 2022-01-10 | NCT03863860 |
| ImmunoGen, Inc. | Mirvetuximab Soravtansine | — | COMPLETED | 2021-11-16 | NCT04296890 |
| Roche | Paclitaxel | Microtubule Inhibitor [EPC] | COMPLETED | 2021-05-26 | NCT03635489 |
| AstraZeneca | Active Comparator: Olaparib tablets | — | COMPLETED | 2021-02-15 | NCT03106987 |
| AGO Research GmbH | Carboplatin | Platinum-based Drug [EPC] | COMPLETED | 2021-01 | NCT01837251 |
| pharmaand GmbH | Chemotherapy | — | COMPLETED | 2020-12-03 | NCT02855944 |
| AB Science | Masitinib | — | COMPLETED | 2020-12 | NCT02490488 |
| AstraZeneca | Olaparib | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | COMPLETED | 2020-10-02 | NCT03402841 |
| On Target Laboratories, LLC | OTL38 | — | COMPLETED | 2020-04-16 | NCT03180307 |
| ImmunoGen, Inc. | Mirvetuximab soravtansine | — | COMPLETED | 2019-01 | NCT02631876 |
| PharmaMar | Lurbinectedin (PM01183) | — | COMPLETED | 2018-10-12 | NCT02421588 |
| AstraZeneca | OLAPARIB | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | COMPLETED | 2018-10-10 | NCT02282020 |
| Pfizer | avelumab | Programmed Death Ligand-1 Blocker [EPC] | COMPLETED | 2018-09-19 | NCT02580058 |
| pharmaand GmbH | Rucaparib | — | COMPLETED | 2017-04-01 | NCT01968213 |
| Tesaro, Inc. | Active comparator: Niraparib | — | COMPLETED | 2016-04-22 | NCT01847274 |
| Roche | Paclitaxel | Microtubule Inhibitor [EPC] | COMPLETED | 2015-03 | NCT01239732 |
| Roche | Gemcitabine (Chemotherapy) | — | COMPLETED | 2015-01-30 | NCT01684878 |
| Roche | Bevacizumab | Vascular Endothelial Growth Factor Inhibitor [EPC] | COMPLETED | 2014-07-09 | NCT00976911 |
| Oasmia Pharmaceutical AB | Paclical® | — | COMPLETED | 2013-10 | NCT00989131 |
| Amgen | AMG 386 | — | COMPLETED | 2013-03 | NCT01204749 |
| Novartis | Pazopanib | — | COMPLETED | 2012-07-08 | NCT00866697 |
| Sutro Biopharma, Inc. | Luveltamab tazevibulin | — | TERMINATED | 2025-08-26 | NCT05870748 |
| Mural Oncology, Inc | Nemvaleukin and Pembrolizumab Combination | — | TERMINATED | 2025-01-08 | NCT05092360 |
| Mersana Therapeutics | Upifitimab rilsodotin | — | TERMINATED | 2023-09-29 | NCT05329545 |
| Aravive, Inc. | Batiraxcept | — | TERMINATED | 2023-08-04 | NCT04729608 |
| Novartis | Alpelisib | PIK3CA | TERMINATED | 2023-04-21 | NCT04729387 |
| Pfizer | Chemotherapy + avelumab followed by avelumab + talazoparib | — | TERMINATED | 2021-12-22 | NCT03642132 |
| AGO Research GmbH | Carboplatin | Platinum-based Drug [EPC] | TERMINATED | 2021-03-03 | NCT03690739 |
| AbbVie | Veliparib | — | TERMINATED | 2019-05-03 | NCT02470585 |
| Pfizer | carboplatin | Platinum-based Drug [EPC] | TERMINATED | 2018-09-07 | NCT02718417 |
| Mateon Therapeutics | Fosbretabulin tromethamine | — | TERMINATED | 2017-10 | NCT02641639 |
| Amgen | AMG 386 | — | TERMINATED | 2016-03 | NCT01493505 |
| Pfizer | MEK162, MEK inhibitor; oral | — | TERMINATED | 2016-01-20 | NCT01849874 |
| Endocyte | EC145 | — | TERMINATED | 2015-05-31 | NCT01170650 |
| Amgen | AMG386 plus PLD | — | TERMINATED | 2014-08-29 | NCT01281254 |
| Xian-Janssen Pharmaceutical Ltd. | CAELYX | — | TERMINATED | 2014-05 | NCT01840943 |
| Morphotek | Farletuzumab | — | TERMINATED | 2012-12-31 | NCT00849667 |
| SOTIO a.s. | DCVAC/OvCa | — | WITHDRAWN | 2021-08 | NCT03905902 |
| Cordgenics, LLC | Chemotherapy | — | WITHDRAWN | 2019-06-10 | NCT03632798 |
| AstraZeneca | OLAPARIB | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | WITHDRAWN | 2019-06 | NCT02392676 |
Showing 100 of 293 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| InxMed (Shanghai) Co., Ltd. | IN10018 in combination with PLD | — | RECRUITING | 2026-05-31 | NCT05551507 |
| AbbVie | Mirvetuximab Soravtansine | — | RECRUITING | 2026-06 | NCT06365853 |
| Portage Biotech | TT-10 | — | RECRUITING | 2026-06-01 | NCT04969315 |
| Medicenna Therapeutics, Inc. | MDNA11 | — | RECRUITING | 2026-06-30 | NCT05086692 |
| Corcept Therapeutics | Relacorilant 150 mg once daily (QD) | — | RECRUITING | 2026-08 | NCT06906341 |
| AtlasMedx, Incorporated | AMXI-5001:Dose Escalation Phase I | — | RECRUITING | 2026-08 | NCT04503265 |
| Heronova Pharmaceuticals | DC05F01 | — | RECRUITING | 2026-08 | NCT06873555 |
| PMV Pharmaceuticals, Inc | rezatapopt | — | RECRUITING | 2026-08-15 | NCT04585750 |
| 858 Therapeutics, Inc. | ETX-19477 | — | RECRUITING | 2026-12 | NCT06395519 |
| Artios Pharma Ltd | ART0380 | — | RECRUITING | 2026-12 | NCT04657068 |
| InxMed (Shanghai) Co., Ltd. | IN10018 | — | RECRUITING | 2026-12-24 | NCT06014528 |
| Shanghai Jiaolian Drug Research and Development Co., Ltd | B013 | — | RECRUITING | 2026-12-31 | NCT06434610 |
| Shanghai Henlius Biotech | HLX43 | — | RECRUITING | 2026-12-31 | NCT06769152 |
| Evopoint Biosciences Inc. | XNW28012 | — | RECRUITING | 2026-12-31 | NCT06799637 |
| Jazz Pharmaceuticals | Zanidatamab | — | RECRUITING | 2026-12-31 | NCT06695845 |
| BioInvent International AB | BI-1808 | — | RECRUITING | 2026-12-31 | NCT04752826 |
| MacroGenics | Lorigerlimab | — | RECRUITING | 2027-02 | NCT06730347 |
| Beijing Biotech | Dual-target CAR-NK cell product | — | RECRUITING | 2027-02-17 | NCT07480954 |
| Compugen Ltd | COM701 | — | RECRUITING | 2027-03 | NCT06888921 |
| Allarity Therapeutics | 2X-121 | — | RECRUITING | 2027-03 | NCT03878849 |
| Beijing Biotech | EB-DUALNK | — | RECRUITING | 2027-03-14 | NCT07589543 |
| Regeneron | REGN5668 | — | RECRUITING | 2027-03-25 | NCT04590326 |
| Apollo Therapeutics Ltd | APL-5125 | — | RECRUITING | 2027-04 | NCT06399757 |
| Incyte Corporation | INCB123667 | — | RECRUITING | 2027-04-27 | NCT07023627 |
| ImmunityBio, Inc. | Gemcitabine | — | RECRUITING | 2027-05 | NCT06710288 |
| Regeneron | Ubamatamab | — | RECRUITING | 2027-05-10 | NCT03564340 |
| Imunon | Paclitaxel | Microtubule Inhibitor [EPC] | RECRUITING | 2027-06-30 | NCT05739981 |
| Genmab | Rina-S | — | RECRUITING | 2027-07 | NCT05579366 |
| Incyclix Bio | INX-315 | — | RECRUITING | 2027-07 | NCT05735080 |
| AstraZeneca | AZD8421 | — | RECRUITING | 2027-08-04 | NCT06188520 |
| Daiichi Sankyo | HER3-DXd | — | RECRUITING | 2027-09-01 | NCT06172478 |
| AstraZeneca | AZD8205 | — | RECRUITING | 2027-09-29 | NCT05123482 |
| TORL Biotherapeutics, LLC | TORL-1-23 | — | RECRUITING | 2027-10 | NCT06690775 |
| Akeso | AK112 low dose | — | RECRUITING | 2027-10 | NCT06686030 |
| AstraZeneca | Datopotamab deruxtecan (Dato-DXd) | — | RECRUITING | 2027-10-01 | NCT05489211 |
| Filamon LTD | A novel hGIIA-Vimentin Inhibitor | — | RECRUITING | 2027-10-26 | NCT06926075 |
| Radiopharm Theranostics, Ltd | 177Lu-BetaBart | — | RECRUITING | 2027-12 | NCT07189871 |
| Tubulis GmbH | TUB-040 | — | RECRUITING | 2027-12 | NCT06303505 |
| TORL Biotherapeutics, LLC | — | — | RECRUITING | 2027-12 | NCT07322094 |
| Nanjing Leads Biolabs Co.,Ltd | LBL-024 for Injection | — | RECRUITING | 2027-12-25 | NCT07042802 |
| AbbVie | IMGN151 | — | RECRUITING | 2028-01 | NCT07024784 |
| Jacobio Pharmaceuticals Co., Ltd. | JAB-8263 | — | RECRUITING | 2028-01 | NCT04686682 |
| AGO Research GmbH | olaparib | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | RECRUITING | 2028-01 | NCT04644289 |
| AstraZeneca | AZD5335 | — | RECRUITING | 2028-01-06 | NCT05797168 |
| Perspective Therapeutics | [203Pb]Pb-PSV359 | — | RECRUITING | 2028-01-31 | NCT06710756 |
| Blue Earth Diagnostics | [18F]FPyQCP | — | RECRUITING | 2028-01-31 | NCT07432633 |
| Avenzo Therapeutics, Inc. | AVZO-021 | — | RECRUITING | 2028-01-31 | NCT05867251 |
| Oncoinvent Solutions AS | Radspherin | — | RECRUITING | 2028-02-29 | NCT06504147 |
| Theolytics Limited | THEO-260 | — | RECRUITING | 2028-06 | NCT06618235 |
| A2 Biotherapeutics Inc. | A2B694 | — | RECRUITING | 2028-06 | NCT06051695 |
| Tanabe Pharma America, Inc. | MT-4561 | — | RECRUITING | 2028-08 | NCT06943521 |
| Regeneron | Ubamatamab | — | RECRUITING | 2028-10-30 | NCT06787612 |
| Acerand Therapeutics (Shanghai) Limited | ACE-86225106 tablet | — | RECRUITING | 2028-12-21 | NCT06380660 |
| Terremoto Biosciences Inc. | TER-2013 | — | RECRUITING | 2028-12-30 | NCT07109726 |
| AbbVie | Mirvetuximab Soravtansine | — | RECRUITING | 2029-01 | NCT07059845 |
| Merck | Raludotatug Deruxtecan | — | RECRUITING | 2029-03-27 | NCT06843447 |
| AstraZeneca | AZD6750 | — | RECRUITING | 2029-10-02 | NCT07115043 |
| AbbVie | Carboplatin | Platinum-based Drug [EPC] | RECRUITING | 2030-02 | NCT06890338 |
| Akeso | AK104 | — | RECRUITING | 2026-05-01 | NCT06560112 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | SHR-A1811 | — | RECRUITING | 2026-05 | NCT06840002 |
| Innolake Biopharm | ILB-2109 | — | RECRUITING | 2026-01-25 | NCT05955105 |
| Hansoh BioMedical R&D Company | HS-20089 | — | RECRUITING | 2025-12-31 | NCT06014190 |
| GI Innovation, Inc. | GI-102 subcutaneous (SC) | — | RECRUITING | 2025-11-12 | NCT05824975 |
| Cybrexa Therapeutics | CBX-12 | — | RECRUITING | 2025-10 | NCT06315491 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | SSGJ-707 | — | RECRUITING | 2025-08 | NCT06522828 |
| Evopoint Biosciences Inc. | XNW27011 | — | RECRUITING | 2025-06-30 | NCT06792435 |
| OncoC4, Inc. | ONC-392 | — | ACTIVE NOT RECRUITING | 2026-06-30 | NCT04140526 |
| BicycleTx Limited | BT5528 | — | ACTIVE NOT RECRUITING | 2026-07-31 | NCT04180371 |
| USWM CT, LLC | — | — | ACTIVE NOT RECRUITING | 2026-08-12 | NCT05601752 |
| OncoC4, Inc. | ONC-392 | — | ACTIVE NOT RECRUITING | 2026-08-30 | NCT05446298 |
| CanariaBio Inc. | Oregovomab | — | ACTIVE NOT RECRUITING | 2026-10-15 | NCT05605535 |
| AbbVie | Mirvetuximab soravtansine | — | ACTIVE NOT RECRUITING | 2026-11 | NCT05456685 |
| CanariaBio Inc. | Oregovomab | — | ACTIVE NOT RECRUITING | 2026-12-30 | NCT05335993 |
| Klus Pharma Inc. | SKB264 | — | ACTIVE NOT RECRUITING | 2026-12-31 | NCT04152499 |
| Pfizer | PF-07104091 monotherapy dose escalation | — | ACTIVE NOT RECRUITING | 2026-12-31 | NCT04553133 |
| TILT Biotherapeutics Ltd. | TILT-123 | — | ACTIVE NOT RECRUITING | 2027-03 | NCT05271318 |
| Nuvation Bio Inc. | NUV-1511 | — | ACTIVE NOT RECRUITING | 2027-03 | NCT06334432 |
| AstraZeneca | AZD5305 | — | ACTIVE NOT RECRUITING | 2027-05-28 | NCT04644068 |
| Sensei Biotherapeutics, Inc. | SNS-101 (anti-VISTA) | — | ACTIVE NOT RECRUITING | 2027-06 | NCT05864144 |
| Ascendis Pharma Oncology Division A/S | TransCon IL-2 β/γ | — | ACTIVE NOT RECRUITING | 2027-08 | NCT05081609 |
| Roche | Ipatasertib | — | ACTIVE NOT RECRUITING | 2028-02-28 | NCT04931342 |
| TCR2 Therapeutics | TC-510 | — | ACTIVE NOT RECRUITING | 2028-10-30 | NCT05451849 |
| Gradalis, Inc. | Vigil | — | ACTIVE NOT RECRUITING | 2028-12 | NCT02346747 |
| Roche | Entrectinib | ALK/ROS1/NTRK1/TRKB/TRKC | ACTIVE NOT RECRUITING | 2026-05-14 | NCT02568267 |
| Verastem, Inc. | Avutometinib (VS-6766) + Defactinib (VS-6063) | — | ACTIVE NOT RECRUITING | 2025-12 | NCT06682572 |
| CanariaBio Inc. | Oregovomab | — | ACTIVE NOT RECRUITING | 2025-10-30 | NCT04938583 |
| Salubris Biotherapeutics Inc | JK08 | — | ACTIVE NOT RECRUITING | 2025-10-17 | NCT05620134 |
| Xencor, Inc. | vudalimab | — | ACTIVE NOT RECRUITING | 2025-10-15 | NCT05032040 |
| EMD Serono Research & Development Institute, Inc. | Tuvusertib (M1774) | — | ACTIVE NOT RECRUITING | 2025-09-29 | NCT06433219 |
| NextCure, Inc. | NC410 | — | ACTIVE NOT RECRUITING | 2025-07 | NCT05572684 |
| Takeda | TAK-853 | — | ACTIVE NOT RECRUITING | 2025-04-16 | NCT06390995 |
| 23andMe, Inc. | 23ME-00610 | — | ACTIVE NOT RECRUITING | 2025-03 | NCT05199272 |
| NGM Biopharmaceuticals, Inc | NGM707 | — | ACTIVE NOT RECRUITING | 2025-02 | NCT04913337 |
| TCR2 Therapeutics | gavo-cel | — | ACTIVE NOT RECRUITING | 2024-11-19 | NCT03907852 |
| Verastem, Inc. | avutometinib (VS-6766) | — | ACTIVE NOT RECRUITING | 2024-11-15 | NCT04625270 |
| Onconic Therapeutics Inc. | JPI-547 | — | ACTIVE NOT RECRUITING | 2024-11 | NCT05475184 |
| Haihe Biopharma Co., Ltd. | CYH33 | — | ACTIVE NOT RECRUITING | 2024-07-31 | NCT05043922 |
| Imunon | IMNN-001 | — | ACTIVE NOT RECRUITING | 2024-07-25 | NCT03393884 |
| ImmunoVaccine Technologies, Inc. (IMV Inc.) | Cyclophosphamide | DNA | ACTIVE NOT RECRUITING | 2023-12-31 | NCT03836352 |
| Mersana Therapeutics | upifitamab rilsodotin | — | ACTIVE NOT RECRUITING | 2023-05-31 | NCT03319628 |
Showing 100 of 253 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Light Chain Bioscience - Novimmune SA | Biological NI-1801 | — | RECRUITING | 2026-05-30 | NCT05403554 |
| Avacta Life Sciences Ltd | AVA6000 | — | RECRUITING | 2026-06-15 | NCT04969835 |
| Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | SYN818 | — | RECRUITING | 2026-06-30 | NCT06666270 |
| Epsilogen Ltd | MOv18 IgE | — | RECRUITING | 2026-07 | NCT06547840 |
| TORL Biotherapeutics, LLC | TORL-1-23 | — | RECRUITING | 2026-08-31 | NCT05103683 |
| Nurix Therapeutics, Inc. | NX-1607 | — | RECRUITING | 2026-08-31 | NCT05107674 |
| IDEAYA Biosciences | IDE-161 | — | RECRUITING | 2026-10 | NCT05787587 |
| PhotonPharma, Inc. | Innocell Autologous Cellular Immunotherapy | — | RECRUITING | 2026-11 | NCT06366490 |
| Mersana Therapeutics | XMT-1660 | — | RECRUITING | 2026-12 | NCT05377996 |
| NextCure, Inc. | LNCB74 | — | RECRUITING | 2026-12 | NCT06774963 |
| Context Therapeutics Inc. | CT-95 | — | RECRUITING | 2026-12 | NCT06756035 |
| Monopar Therapeutics | MNPR-101-PCTA-177Lu | — | RECRUITING | 2026-12 | NCT06617169 |
| SystImmune Inc. | BL-B01D1 | — | RECRUITING | 2026-12-31 | NCT05983432 |
| Bicara Therapeutics | BCA101 | — | RECRUITING | 2026-12-31 | NCT04429542 |
| Chongqing Precision Biotech Co., Ltd | CD70 CAR-T cells | — | RECRUITING | 2026-12-31 | NCT06215950 |
| Solve Therapeutics | SLV-154 | — | RECRUITING | 2027-01 | NCT06771219 |
| ViroMissile, Inc. | IDOV-Immune (oncolytic vaccinia virus) | — | RECRUITING | 2027-01-31 | NCT06910657 |
| Daewoong Pharmaceutical Co. LTD. | DWZ2501 (Olaparib 150mg) | — | RECRUITING | 2027-03 | NCT07371104 |
| Context Therapeutics Inc. | CTIM-76 | — | RECRUITING | 2027-04-30 | NCT06515613 |
| Accent Therapeutics | ATX-295 | — | RECRUITING | 2027-04-30 | NCT06799065 |
| Eli Lilly | LY4052031 | — | RECRUITING | 2027-05 | NCT06465069 |
| Normunity AccelCo, Inc. | NRM-823 | — | RECRUITING | 2027-05-30 | NCT07182149 |
| OnCusp Therapeutics, Inc. | CUSP06 | — | RECRUITING | 2027-05-30 | NCT06234423 |
| Nerviano Medical Sciences | NMS-03305293 | — | RECRUITING | 2027-05-31 | NCT06930755 |
| AbbVie | Azirkitug | — | RECRUITING | 2027-07 | NCT05005403 |
| Dren Bio | DR-0202 | — | RECRUITING | 2027-07 | NCT06999187 |
| IDEAYA Biosciences | IDE034 | — | RECRUITING | 2027-07-30 | NCT07503808 |
| Theolytics Limited | THEO-260 | — | RECRUITING | 2027-09 | NCT07211659 |
| AstraZeneca | AZD5335 | — | RECRUITING | 2027-10-15 | NCT07402915 |
| Verismo Therapeutics | SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR | — | RECRUITING | 2027-12 | NCT05568680 |
| Xencor, Inc. | XmAb541 | — | RECRUITING | 2027-12 | NCT06276491 |
| Clasp Therapeutics, Inc. | CLSP-1025 | — | RECRUITING | 2027-12 | NCT06778863 |
| Ascentage Pharma Group Inc. | APG-2449 | — | RECRUITING | 2027-12 | NCT03917043 |
| Stemline Therapeutics, Inc. | MEN2501 | — | RECRUITING | 2027-12-02 | NCT07226427 |
| Nammi Therapeutics Inc | QXL138AM Injection every 2 weeks by IV Infusion | — | RECRUITING | 2027-12-31 | NCT06582017 |
| Fate Therapeutics | FT836 | — | RECRUITING | 2028-01 | NCT07216105 |
| Whitehawk Therapeutics, Inc. | HWK-016, MUCIN-16-targeted ADC | — | RECRUITING | 2028-02 | NCT07470853 |
| Chongqing Precision Biotech Co., Ltd | CD70-targeted CAR-T cells | — | RECRUITING | 2028-03-31 | NCT07181720 |
| BeiGene | BG-68501 | — | RECRUITING | 2028-04 | NCT06257264 |
| Regor Pharmaceuticals Inc. | RGT-490 | — | RECRUITING | 2028-04 | NCT07524322 |
| MacroGenics | MGC026 Dose Escalation | — | RECRUITING | 2028-05 | NCT06242470 |
| Outpace Bio, Inc. | OPB-101 | — | RECRUITING | 2028-05-15 | NCT07030907 |
| K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Azenosertib | — | RECRUITING | 2028-06-30 | NCT04516447 |
| ImmVirx Pty Ltd | IVX037 | — | RECRUITING | 2028-06-30 | NCT05427487 |
| Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | SYN818 and Olaparib will be administered | — | RECRUITING | 2028-08-25 | NCT07156253 |
| Whitehawk Therapeutics, Inc. | HWK-007 | — | RECRUITING | 2028-10 | NCT07444814 |
| Bristol-Myers Squibb | BMS-986500 | — | RECRUITING | 2028-12-14 | NCT06997029 |
| SystImmune Inc. | BL-M07D1 | — | RECRUITING | 2028-12-15 | NCT06293898 |
| Bristol-Myers Squibb | BMS-986463 | — | RECRUITING | 2028-12-19 | NCT06476808 |
| NiKang Therapeutics, Inc. | NKT3964 | — | RECRUITING | 2029-01 | NCT06586957 |
| AbbVie | ABBV-901 | — | RECRUITING | 2029-01 | NCT07278336 |
| Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | EXS74539 | — | RECRUITING | 2029-03 | NCT07517198 |
| Pheast Therapeutics | PHST001 | — | RECRUITING | 2029-04 | NCT06840886 |
| Boehringer Ingelheim | BI 3820768 | — | RECRUITING | 2029-04-21 | NCT07306559 |
| AstraZeneca | Autologous, engineered T Cells targeting TP53 R175H | — | RECRUITING | 2029-07-31 | NCT05877599 |
| Conjupro Biotherapeutics, Inc. | SYS6043 | — | RECRUITING | 2029-12 | NCT07424547 |
| Regeneron | Cemiplimab | — | RECRUITING | 2030-05-27 | NCT06469281 |
| Boryung Pharmaceutical Co., Ltd | Olaparib 150 MG | — | RECRUITING | 2026-05-15 | NCT07069335 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-10502 + NHA | — | RECRUITING | 2026-05-07 | NCT06769425 |
| Radiopharm Theranostics, Ltd | RAD301 ([68Ga]-RAD301) | — | RECRUITING | 2026-05 | NCT05799274 |
| Ascentage Pharma Group Inc. | APG -2449 | — | RECRUITING | 2026-05 | NCT06687070 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-10502 | — | RECRUITING | 2026-04-01 | NCT05740956 |
| Monopar Therapeutics | MNPR-101-DFO*-89Zr | — | RECRUITING | 2026-04 | NCT06337084 |
| Shanghai Best-Link Bioscience, LLC | BL0175 | — | RECRUITING | 2026-02-20 | NCT06738966 |
| Chongqing Precision Biotech Co., Ltd | CD70 CAR-T cells | — | RECRUITING | 2025-12-31 | NCT06010875 |
| Molecure S.A. | OATD-02 | — | RECRUITING | 2025-12 | NCT05759923 |
| Oxford Vacmedix UK Ltd. | OVM-200 | — | RECRUITING | 2025-11-30 | NCT05104515 |
| BioEclipse Therapeutics | CRX100 suspension for infusion | — | RECRUITING | 2025-08 | NCT04282044 |
| Toray Industries, Inc | TRK-950 | — | ACTIVE NOT RECRUITING | 2026-06 | NCT03872947 |
| AbbVie | ABBV-400 | — | ACTIVE NOT RECRUITING | 2026-07 | NCT06084481 |
| Boundless Bio, Inc. | BBI-355 | — | ACTIVE NOT RECRUITING | 2026-09-30 | NCT05827614 |
| USWM CT, LLC | — | — | ACTIVE NOT RECRUITING | 2026-12-23 | NCT04044859 |
| TScan Therapeutics, Inc. | TSC-204-A0201 | — | ACTIVE NOT RECRUITING | 2026-12-30 | NCT05973487 |
| Eli Lilly | LY4101174 | — | ACTIVE NOT RECRUITING | 2027-03 | NCT06238479 |
| NeoTX Therapeutics Ltd. | — | — | ACTIVE NOT RECRUITING | 2027-03-01 | NCT03983954 |
| MOMA Therapeutics | MOMA-313 | — | ACTIVE NOT RECRUITING | 2027-05-31 | NCT06545942 |
| SystImmune Inc. | BL-M17D1 | — | ACTIVE NOT RECRUITING | 2027-09-01 | NCT06714617 |
| Atavistik Bio, Inc | ATV-1601 | — | ACTIVE NOT RECRUITING | 2028-08-31 | NCT07038369 |
| Poseida Therapeutics, Inc. | P-MUC1C-ALLO1 CAR-T cells | — | ACTIVE NOT RECRUITING | 2026-04 | NCT05239143 |
| Arcus Biosciences, Inc. | AB598 | — | ACTIVE NOT RECRUITING | 2026-03 | NCT05891171 |
| Nuvectis Pharma, Inc. | NXP800 | — | ACTIVE NOT RECRUITING | 2025-12 | NCT05226507 |
| Theratechnologies | TH1902 | — | ACTIVE NOT RECRUITING | 2025-12 | NCT04706962 |
| NGM Biopharmaceuticals, Inc | NGM831 | — | ACTIVE NOT RECRUITING | 2025-07 | NCT05215574 |
| AstraZeneca | Administration of ceralasertib | — | ACTIVE NOT RECRUITING | 2025-03-04 | NCT02264678 |
| Agenus Inc. | Botensilimab | — | ACTIVE NOT RECRUITING | 2025-01-13 | NCT03860272 |
| Precigen, Inc | PRGN-3005 UltraCAR-T cells | — | ACTIVE NOT RECRUITING | 2024-12-15 | NCT03907527 |
| Shanghai PerHum Therapeutics Co., Ltd. | CCT303-406 | — | ACTIVE NOT RECRUITING | 2024-10-24 | NCT04511871 |
| Exelixis | cabozantinib | AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3 | ACTIVE NOT RECRUITING | 2023-02-21 | NCT03170960 |
| USWM CT, LLC | — | — | ACTIVE NOT RECRUITING | 2022-12-27 | NCT03132922 |
| WestVac Biopharma Co., Ltd. | WSK-IM02 | — | NOT YET RECRUITING | 2027-03-31 | NCT07462468 |
| Chong Kun Dang Pharmaceutical | CKD-215 | — | NOT YET RECRUITING | 2027-06 | NCT07532148 |
| Medigene AG | Lymphodepletion | — | NOT YET RECRUITING | 2027-12-01 | NCT06748872 |
| Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | SYN608 | — | NOT YET RECRUITING | 2028-07-31 | NCT07088588 |
| Xencor, Inc. | XmAb541 | — | NOT YET RECRUITING | 2028-12 | NCT07593092 |
| Aromics Therapeutics | AROG4-01 | — | NOT YET RECRUITING | 2025-12 | NCT06652529 |
| Compugen Ltd | Dose escalation: COM902 monotherapy. | — | COMPLETED | 2026-04-01 | NCT04354246 |
| SN BioScience | SNB-101 | — | COMPLETED | 2026-01-05 | NCT04640480 |
| Oncoinvent Solutions AS | Radspherin | — | COMPLETED | 2025-09-30 | NCT03732768 |
| MacroGenics | vobramitamab duocarmazine | — | COMPLETED | 2025-06-24 | NCT05293496 |
| Risen (Suzhou) Pharma Tech Co., Ltd. | RP903 | — | COMPLETED | 2025-05-30 | NCT06846099 |
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Ovarian Cancer
Novel Drugs by Company (New molecular entities)
Reformulations (6 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Drug Targets
Generic Drugs (1 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs